What's new? Log in Free sign up

Filing search / VYNE Therapeutics Inc. / "Pandemic"

Search information

VYNE Therapeutics Inc.

Companies

"Pandemic"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

77 results

Newest first Best match first

VYNE VYNE Therapeutics Inc.

Quarterly report

employees on their payroll during the COVID-19 pandemic and allowed eligible employers to claim a refundable tax credit against the employer share

7 Nov 24

4:07pm

VYNE VYNE Therapeutics Inc.

Quarterly report

was a refundable tax credit against certain employment taxes for qualifying businesses retaining employees on their payroll during the COVID-19 pandemic and allowed

14 Aug 24

4:01pm

VYNE VYNE Therapeutics Inc.

Quarterly report

was a refundable tax credit against certain employment taxes for qualifying businesses retaining employees on their payroll during the COVID-19 pandemic

9 May 24

4:01pm

VYNE VYNE Therapeutics Inc.

taxes for qualifying businesses retaining employees on their payroll during the COVID-19 pandemic and allowed eligible employers to claim a refundable

1 Mar 24

4:01pm

VYNE VYNE Therapeutics Inc.

Quarterly report

retaining employees on their payroll during the COVID-19 pandemic and allows eligible employers to claim a refundable tax credit against the employer … pandemic during the commercial launches of both AMZEEQ and ZILXI, the payor landscape, as well as the costs to develop each of its pipeline products

13 Nov 23

7:57am

bp161iyfyr nam9

Quarterly report

14 Aug 23

4:02pm

Quarterly report

14 Aug 23

4:02pm

1zz5hsboxu hf61y68r

Quarterly report

11 May 23

4:24pm

Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development

0r6zhqbgczwqv84hl qb

Quarterly report

14 Nov 22

4:15pm

02y18kjx62pqmmuo6t8

VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

b30 6103surx9cww50

VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Quarterly report

12 Aug 22

4:25pm

m371mt4ttjgv2mmfcrpz

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

77l8zy kzohzwqc32fks

Regulation FD Disclosure

gcqldgkbzychfuda5

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

6jdwx0k47c1bztg4y5l

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

Regulation FD Disclosure

Quarterly report

12 May 22

4:22pm

Prev
1
2
3
4
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.